ArticleJTO clinical and research reports2026
Yttrium-90 Radioembolization Versus Transarterial Embolization for Lung Carcinoid Hepatic Metastasis.
Article in JTO clinical and research reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Objective: To compare the safety and efficacy of transarterial embolization (TAE) and transarterial radioembolization (TARE) in the treatment of lung carcinoid liver metastasis. Method: This retrospective, single-institution study included 30 patients with lung carcinoid liver metastasis treated with 53 primary embolization procedures (24 TARE; 29 TAE) between 2009 and 2022. Survival analyses were performed using the Kaplan-Meier method. Adverse events were assessed using the Common Terminology Criteria of Adverse Events Version 5.0. Results: The local tumor progression-free survival (LTPFS) for the entire cohort was 16.2 (95% confidence interval [CI]: 12.6-22.2) months. Factors associated with poor LTFPS for all patients included chromogranin A positivity (hazard ratio [HR]: 10.13, 95% CI: 2.32-44.31, Conclusion: TARE exhibited better local tumor control compared with TAE in patients with lung carcinoid, with no significant difference in overall survival. Both hepatic arterially directed therapies exhibited acceptable safety profiles.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.